Premium
Clinical Relevance of Antiphospholipid Antibodies in Primary Biliary Cirrhosis
Author(s) -
LANDENBERG PHILIPP,
BAUMGARTNER MICHAEL,
SCHOELMERICH JUERGEN,
LACKNER KARL J.,
KLEIN REINHILD
Publication year - 2005
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1361.043
Subject(s) - primary biliary cirrhosis , autoantibody , anti nuclear antibody , antibody , medicine , autoimmune hepatitis , immunology , gastroenterology , clinical significance , hepatitis
A bstract : Primary biliary cirrhosis (PBC) is a cholestatic liver disease characterized by the presence of antimitochondrial autoantibodies (AMAs), but also with reactivities to other autoantigens. Recent studies showed that antibodies to phospholipids (APAs) represent an important group of autoantibodies identified in patients with PBC. In this study different types of APAs were identified in the sera of patients with PBC and autoimmune hepatitis (AIH) and control subjects. Sera from patients with PBC and AIH were tested for the presence of antibodies directed against cardiolipin (CL), phosphatidylserine (PS), and to β 2 ‐glycoprotein I (β 2 ‐GPI). Furthermore, an in‐house test for antithromboplastin antibodies was performed. Antinuclear antibodies (ANAs) and antimitochondrial antibodies (AMAs) were tested with standard tests. IgM anti‐PS antibodies were found in 75% of the 51 PBC patients, but only in 4% of the 48 AIH patients ( P < 0.0001 ). IgM anti‐CL antibodies were more frequently detected in AIH than in PBC (75% vs. 89%; P = 0.045 ). IgM anti‐β 2 ‐GPI antibodies were observed more frequently in patients with AIH (83%) than with PBC (59%; P = 0.007 ). The APAs of the IgG type did not differ significantly between the groups of patients. Considering the clinical/laboratory parameters, the levels of alkaline phosphatase ( P = 0.017 ), glutamate pyruvate transaminase ( P = 0.035 ), and glutamate oxalacetate transaminase ( P = 0.034 ) were significantly higher in PBC patients who were positive for IgM anti‐PS antibodies than in the anti‐PS antibody‐negative patients. In conclusion, APAs are present in PBC patients with a higher level of the disease or more intense liver damage than in patients without APAs. Thus IgM anti‐PS antibodies represent a new marker of activity in PBC patients.